Xenon Getting $41M Up Front in Teva Pain Collaboration
By Catherine Shaffer
Wednesday, December 12, 2012
Teva Pharmaceuticals Industries Ltd., of Jerusalem, teamed up with Xenon Pharmaceuticals Inc., of Burnaby, British Columbia, for the licensing of Xenon's sodium channel targeted drug, XEN402.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.